AT-001
Международное непатентованное наименование
AT-001
Торговое наименование
-
Производитель, страна
NYU Langone Health, USA
Механизм действия
AT-001 is an aldose reductase inhibitor that has demonstrated potential therapeutic effects on diabetic cardiomyopathy. Given the involvement of the heart in individuals with severe COVID-19 complications, AT-001 is being tested to see how it can impact the cardiac structure, function, and survival of COVID-19 patients.
Публикации COVID-19
JACC Case Rep. 2020 May 3. doi: 10.1016/j.jaccas.2020.04.025.
Angeliki M.Angelidi, Matthew J.Belanger, Christos S.Mantzoros. COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism. 19 April 2020, 154245. DOI: 10.1016/j.metabol.2020.154245.
Клинические исследования
1.
Название протокола
A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection
Дата начала и окончания КИ
April 8, 2020 - December 31, 2020
Название организации, проводящей КИ
NYU Langone Health
Страны
USA
Фаза
II
Кол-во пациентов
500